Editorial: Nanomedicine in Cancer Targeting and Therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Nanotechnological innovations in dermo-cosmetics: lessons for nanomedicine advancement.Nanomedicine (London, England) · 2024
   Article
2. Prevention of chemotherapy-related bone loss with doxorubicin-loaded solid lipid nanoparticles.Nanomedicine (London, England) · 2024
   Article
3. Application of Nanomedicine in Immunotherapy: Recent Advances and Prospects.Pharmaceutics · 2023
   Article
4. A review of nanomaterials from synthetic and natural molecules for prospective breast cancer nanotherapy.Frontiers in pharmacology · 2023
   Review
5. Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office.Pharmaceutics · 2022
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as